EP2149554A1 - Indolylamides en tant que modulateurs du récepteur EP2 - Google Patents

Indolylamides en tant que modulateurs du récepteur EP2 Download PDF

Info

Publication number
EP2149554A1
EP2149554A1 EP08161444A EP08161444A EP2149554A1 EP 2149554 A1 EP2149554 A1 EP 2149554A1 EP 08161444 A EP08161444 A EP 08161444A EP 08161444 A EP08161444 A EP 08161444A EP 2149554 A1 EP2149554 A1 EP 2149554A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
acyl
con
cycloalkyl
nhch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08161444A
Other languages
German (de)
English (en)
Inventor
Bernd Buchmann
Nico BRÄUER
Marcus Dr. Koppitz
Antonius Dr. Ter Laak
Bernhard Dr. Lindenthal
Gernot Dr. Langer
Tim Dr. Wintermanter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Priority to EP08161444A priority Critical patent/EP2149554A1/fr
Priority to PCT/EP2009/005267 priority patent/WO2010012399A1/fr
Publication of EP2149554A1 publication Critical patent/EP2149554A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Definitions

  • the present invention relates to indolylamide derivatives as EP 2 receptor modulators, processes for their preparation and their use as medicaments.
  • prostaglandins key molecules in the processes of female reproductive biology, such as. The regulation of ovulation, fertilization, nidation, decidualization (e.g., plaque formation), and menstruation. Prostaglandins also play an important role in the pathological changes in the reproductive tract, including menorrhagia, dysmenorrhea, endometriosis and cancer. So far, the mechanism by which prostaglandins cause these changes is not fully understood. Recent evidence indicates that prostaglandins, their receptors and their signal transduction pathways are involved in processes such as angiogenesis, apoptosis, proliferation and inflammatory / anti-inflammatory and immunological processes.
  • prostaglandins are mediated by their G protein-coupled receptors located on the cell surface.
  • PGE 2 prostaglandin E 2
  • the receptor subtypes to which the prostaglandin binds E 2 appear to be of particular interest for the receptor-mediated effects involved in fertility regulation.
  • EP 2 knock-out mice EP 2 knock-out mice
  • these EP 2 knock-out mice Hizaki et al. Proc Natl Acad Sci USA 1999 Aug 31; 96 (18): 10501-10506
  • the EP 2 receptor therefore represents an important target for the development of drugs for the regulation of female fertility.
  • the existence of the 4 subclasses of the PGE 2 receptor opens up the possibility for the targeted development of selectively active compounds. So far, however, hardly any selective EP 2 receptor ligands are known which bind to the EP 2 subtypes of the PGE 2 receptor, since most of the known compounds are also linked to the other PGE 2 receptor subtypes, for example to EP 4 Receptor, bind.
  • EP 2 receptor antagonists are used, for example, in the applications US2005059742 and EP1467738 described (Jabbour, Medical Research Concil). Claimed is a method in which an EP 2 and / or an EP 4 antagonist for the treatment of menorrhagia and dysmenorrhea can be used. AH6809 is disclosed as an antagonist of the EP 2 or EP 4 receptor, no other specific antagonists and no new compounds are disclosed.
  • Naphthalene derivatives as EP 4 receptor ligands are available from SmithKline Beecham Corporation in the application US2004102508 disclosed.
  • the claimed compounds find their use for the treatment or prophylaxis of pain, allergic reactions and neurodegenerative diseases.
  • EP 4 antagonists ( ⁇ -lactams) are mentioned in the application WO03 / 103604 claims (Applied Research Systems).
  • the compounds bind approximately 60 times better to the EP 4 than to the EP 2 receptor and are claimed, inter alia, for the treatment of premature labor, dysmenorrhea, asthma, infertility or fertility disorders.
  • the same company will appear in the applications WO03 / 053923 (substituted pyrrolidines) or WO03 / 035064 (substituted pyrazolidiones) compounds for the treatment of diseases associated with prostaglandins, such as infertility, hypertension and osteoporosis claims.
  • the compounds bind to the EP 4 and to the EP 2 receptor subtypes.
  • WO03 / 037433 are claimed ⁇ -cycloalkyl, 17 heteroaryl prostaglandin derivatives as EP 2 receptor antagonists, in particular for the treatment of elevated intraocular pressure.
  • Tani et al claim in the application US2005124577 8- Azaprostaglandinderivate for the treatment of immunological diseases, allergic diseases, premature labor, abortion, etc.
  • the compounds bind to the EP 2 and to the EP 4 receptor.
  • EP 1306087 EP 2 receptor agonists are described which find their use in the treatment of erectile dysfunction (Ono Pharmaceuticals).
  • the same structural class is used in the European patent EP 860430 (Ono Pharmaceuticals), their use for the manufacture of a medicament for the treatment of immunological diseases, asthma and abortion is claimed.
  • EP 2 and EP 4 receptor agonists are described for the treatment of diseases caused by uterine contraction, for example menstrual disorders (Ono Pharmaceuticals).
  • EP 2 and EP 4 receptor are frequently described in connection with the treatment of osteoporosis ( WO99 / 19300 (Pfizer), US2003 / 0166631 (Dumont Francis ) WO03 / 77910 (Pfizer), WO03 / 45371 (Pfizer), WO03 / 74483 and WO03 / 09872 (Ono Pharmaceuticals)) and for glaucoma treatment ( WO04 / 37813 . WO04 / 37786 . WO04 / 19938 . WO03 / 103772 . WO03 / 103664 . WO03 / 40123 . WO03 / 47513 . WO03 / 47417 (Merck Frosst Canada) and US6410591 . US6747037 (Allergan)).
  • the object of the present invention was therefore to provide more potent, selective antagonists of the EP 2 receptor.
  • the compounds of the invention have an antagonistic effect on the EP 2 receptor and thus serve the purpose of female fertility control.
  • C 1 -C 4 -alkyl or C 1 -C 6 -alkyl is in each case a straight-chain or branched alkyl radical, such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec. Butyl, tert. Butyl, pentyl, isopentyl and hexyl, to understand.
  • the alkyl radicals may optionally be monosubstituted or polysubstituted, identically or differently, by halogen.
  • C 1 -C 4 -alkoxy or C 1 -C 6 -alkoxy is in each case a straight-chain or branched alkoxy radical, such as, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec- Butoxy, iso-butoxy, tert. Butyloxy, pentoxy, iso-pentoxy and hexoxy, to understand.
  • the alkoxy radicals may optionally be monosubstituted or polysubstituted by the same or different halogen.
  • C 1 -C 4 -acyl or C 1 -C 6 -acyl is in each case to be understood as meaning a straight-chain or branched radical, such as, for example, formyl, acetyl, propionyl, butyroyl, isobutyl, valeroyl and benzoyl.
  • the acyl radicals may optionally be monosubstituted or polysubstituted, identically or differently, by halogen.
  • C 3 -C 6 -cycloalkyl are meant monocyclic alkyl rings such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • the cycloalkylyl radicals may contain one or more heteroatoms, such as oxygen, sulfur and / or nitrogen, instead of the carbon atoms. Preference is given to those heterocycloalkyls having 3 to 6 ring atoms, for example aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl.
  • ring systems which may optionally contain one or more possible double bonds in the ring are, for example, cycloalkenyls such as cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cycloheptenyl to understand the attachment to both the double bond and to the single bonds can be done.
  • cycloalkenyls such as cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cycloheptenyl to understand the attachment to both the double bond and to the single bonds can be done.
  • Halogen is in each case fluorine, chlorine, bromine or iodine.
  • the C 6 -C 12 aryl radical comprises in each case 6 to 12 carbon atoms and may be benzo-fused, for example. Examples include: phenyl, tropyl, cyclooctadienyl, indenyl, naphthyl, biphenyl, fluorenyl, anthracenyl, etc.
  • the monocyclic C 5 -C 12 heteroaryl radical is to be understood as meaning ring systems which each contain 5 to 16 ring atoms and which instead of the carbon may contain one or more, identical or different heteroatoms, such as oxygen, sulfur or nitrogen, and the C 5 -C 16 heteroaryl may be mono-, bi- or tricyclic and may additionally be benzo-fused in each case.
  • the heteroaryl radical may each be benzo-fused.
  • Heteroatoms are oxygen, nitrogen or sulfur atoms.
  • suitable salts are the physiologically tolerated salts of organic and inorganic bases, such as, for example, the readily soluble alkali and alkaline earth salts and N-methyl-glucamine, dimethylglucamine, ethyl-glucamine, lysine, 1,6-hexadiamine, ethanolamine , Glucosamine, sarcosine, serinol, tris-hydroxy-methyl-amino-methane, aminopropanediol, Sovak base, 1-amino-2,3,4-butanetriol.
  • organic and inorganic bases such as, for example, the readily soluble alkali and alkaline earth salts and N-methyl-glucamine, dimethylglucamine, ethyl-glucamine, lysine, 1,6-hexadiamine, ethanolamine , Glucosamine, sarcosine, serinol, tris-hydroxy-methyl-amino-methane, aminopropaned
  • physiologically acceptable salts of organic and inorganic acids are suitable, such as hydrochloric acid, sulfuric acid, phosphoric acid, citric acid, tartaric acid and the like.
  • the present invention relates to the use of the compounds according to the invention for the preparation of medicaments which contain at least one of the compounds according to formula I.
  • medicaments containing the compounds according to the invention with suitable formulation and carrier substances.
  • the new EP 2 agonists and antagonists are characterized by greater selectivity and stability.
  • the present invention relates to medicaments for the treatment and prophylaxis of diseases which include fertility disorders, infectious diseases, cancer, viral infections, cardiovascular diseases, increased intraocular pressure, glaucoma, diseases of the bone apparatus, angiogenic disorders, disorders of the contraction of the uterus, pain, neuroinflammatory diseases, immunomodulatory infections and nephrological diseases.
  • diseases which include fertility disorders, infectious diseases, cancer, viral infections, cardiovascular diseases, increased intraocular pressure, glaucoma, diseases of the bone apparatus, angiogenic disorders, disorders of the contraction of the uterus, pain, neuroinflammatory diseases, immunomodulatory infections and nephrological diseases.
  • Fertility disorders are diseases that cause no ovulation, no fertilization of a fertilized egg and no decidualisation, infectious diseases, unicellular parasite-related diseases, cancerous tumors and leukemia, viral Infections z. Cytomegalovirus infections, hepatitis, hepatitis B and C and HIV diseases, among immunomodulatory infections e.g. Avian flu, cardiovascular diseases, ischemic reperfusion disease, stenoses, atherosclerosis and restenosis, angiogenic diseases e.g. Endometriosis and fibrosis, with increased intraocular pressure glaucoma, with disorders of uterine contraction e.g.
  • immunomodulatory infections e.g. Avian flu, cardiovascular diseases, ischemic reperfusion disease, stenoses, atherosclerosis and restenosis, angiogenic diseases e.g. Endometriosis and fibrosis, with increased intraocular pressure glaucoma, with disorders of uterine contraction e.g
  • Menstrual disorders diseases of the bone apparatus, osteoporosis, neuroinflammatory diseases, multiple sclerosis, Alzheimer's disease, Parkinson's disease, Crohn's disease, ulcerative colitis, pain, and nephrological disorders, polycystic kidney disease, glomerulonephritis.
  • medicaments for the treatment and prophylaxis of the abovementioned disorders which contain at least one compound according to the general formula I, as well as medicaments with suitable formulating and carrier substances.
  • a pharmaceutical preparation in addition to the active ingredient for enteral or parenteral administration suitable pharmaceutical, organic or inorganic inert carrier materials, such as, for example, water, gelatin, gum arabic, lactose, starch , Magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc.
  • suitable pharmaceutical, organic or inorganic inert carrier materials such as, for example, water, gelatin, gum arabic, lactose, starch , Magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc.
  • the pharmaceutical preparations may be in solid form, for example as tablets, dragees, suppositories, capsules, in semi-solid form, for example as ointments, Creams, gels, suppositories, emulsions or in liquid form, for example as solutions, suspensions or emulsions.
  • auxiliaries which are intended to act, for example, as fillers, binder, disintegrant, lubricant, solvent, solubilizer, flavoring agent, dye, emulsifier.
  • Auxiliaries for the purposes of the invention are, for example, saccharides (mono-, di-, tri-, oligo- and / or polysaccharides), fats, waxes, oils, hydrocarbons, anionic, nonionic, cationic natural, synthetic or semisynthetic surfactants.
  • they also contain adjuvants, such as preservatives, stabilizers, wetting agents or emulsifiers; Salts for changing the osmotic pressure or buffer.
  • tablets, dragees or capsules with talc and / or hydrocarbon carriers or binders, such as lactose, corn or potato starch are suitable.
  • the application can also take place in liquid form, for example as juice, which may be accompanied by a sweetener.
  • Clathrates are likewise suitable for the oral administration of such compounds, examples being the clathrates with alpha-, beta-, gamma-cyclodextrin or else beta-hydroxypropyl-cyclodextrin.
  • sterile, injectable, aqueous or oily solutions are used for parenteral administration.
  • Particularly suitable are injection solutions or suspensions, in particular aqueous solutions of the active compounds in polyethoxylated castor oil.
  • vaginal administration For vaginal administration z. As suppositories, tampons or an intrauterine system suitable and common.
  • crystal suspensions For intraarticular injection, appropriately prepared crystal suspensions may be used.
  • aqueous and oily injection solutions or suspensions and corresponding depot preparations can be used.
  • the new compounds may be used in the form of suppositories, capsules, solutions (e.g., in the form of enemas) and ointments for both systemic and local therapy.
  • these can be used in the form of aerosols and inhalants.
  • the new compounds may be used as drops, ointments and tinctures in appropriate pharmaceutical preparations.
  • formulations in gels, ointments, greases, creams, pastes, powders, milk and tinctures are possible.
  • the dosage of the compounds of general formula I should be in these preparations 0.01% - 20% in order to achieve a sufficient pharmacological effect.
  • the dosage of the active ingredients may vary depending on the route of administration, the age and weight of the patient, the nature and severity of the disease being treated, and similar factors. Treatment may be by single doses or by a variety of doses over an extended period of time.
  • the daily dose is 0.5-1000 mg, preferably 50-200 mg, which dose may be given as a single dose to be administered once or divided into 2 or more daily doses.
  • Surfactant auxiliaries such as salts of bile acids or animal or plant phospholipids, but also mixtures thereof and liposomes or components thereof can also be used as carrier systems.
  • Administration of the compounds of the invention may be by any conventional method, including oral and parenteral, e.g. by subcutaneous or intramuscular injections.
  • the enteral, parenteral, vaginal and oral applications are also the subject of the present invention.
  • the compounds of the general formula I according to the invention bind to the EP 2 receptor and have agonistic or antagonistic action. It can be determined by an agonism test (see Example 1.2.1 of the biological examples) or by an antagonism test (see Example 1.2.2 of the biological examples) whether an agonistic or antagonistic effect is present.
  • antagonists are meant those molecules which bind to their respective receptors and which inhibit the initiation of the receptor coupled signal transduction pathways by the or the naturally occurring ligand (s).
  • the antagonists compete with the naturally occurring ligand of the receptor for binding to the receptor.
  • other modifications of the receptor by molecules that prevent the receptor-coupled signal transduction pathways from being activated by the naturally occurring ligand or ligands are also possible (eg, non-competitive, steric modifications of the receptor).
  • Receptor antagonists typically bind selectively to their particular receptor and not to other receptors. They usually have a higher binding affinity than the natural ligand. Although antagonists that have a higher affinity for the receptor than the natural ligand are preferred, antagonists with a lower affinity can also be used. Preferably, the antagonists reversibly bind to their corresponding receptors.
  • the EP 2 receptor antagonist has a preferential affinity for the EP 2 receptor over any other EP receptor.
  • Antagonism is measured in the presence of the natural agonist (PGE 2 ).
  • agonists are meant those molecules which bind to their respective receptors and usually compete with the naturally occurring ligand of the receptor for binding to the receptor and which stimulate the initiation of the signal transduction pathway coupled to the receptor. Agonists may also aid in the binding of the natural ligand.
  • Receptor agonists typically bind selectively to their particular receptor and not to other receptors. They usually have a higher binding affinity than the natural ligand. Although agonists that have a higher affinity for the receptor than the natural ligand are preferred, agonists with a lower affinity can also be used. Preferably, the agonists reversibly bind to their corresponding receptors.
  • the EP 2 receptor agonist has a preferential affinity for the EP 2 receptor over any other EP receptor.
  • Agonists are tested via the initiation of the corresponding receptor-mediated signal transduction and / or physiological action.
  • Ligands are the compounds or low molecular weight substances that bind to a receptor. Their binding is usually reversible. By binding a ligand to the corresponding receptor, the signal transduction pathway coupled to the receptor is activated or inactivated. In this way, the ligand mediates its intracellular action. Ligands are to be understood as agonists and antagonists of a receptor.
  • the substances according to the invention as EP 2 receptor antagonists for the treatment of diseases which are caused by disorders in the signal transduction chain in which the EP 2 receptor is involved, such as pain and fertility disorders, and the are also suitable for fertility control.
  • the oocyte In the pre-ovulatory antral follicle, the oocyte is surrounded by cumulus cells, which form a dense cell ring around the egg. After the luteinizing hormone peak (LH peak), a series of processes is activated, which results in a strong morphological change of this cell cluster of cumulus cells. The cumulus cells form an extracellular matrix, which leads to the so-called cumulus expansion ( Vanderhyden et al. Dev Biol. 1990 Aug; 140 (2): 307-317 ). This cumulus expansion is an important part of the ovulatory process and the subsequent possibility of fertilization.
  • LH peak luteinizing hormone peak
  • Prostanoid EP 2 knock-out mice show markedly reduced cumulus expansion and strong subfertility, demonstrating the importance of the prostanoid EP 2 receptor for this process.
  • the substances according to the invention have inhibitory effects in cumulus expansion tests.
  • the present invention is the use of the substances according to the invention for fertility control.
  • Prostaglandins play an important role in angiogenesis ( Sales, Jabbour, 2003, Reproduction 126, 559-567 ; Kuwano et al., 2004, FASEB J. 18, 300-310 ; Kamiyama et al., 2006, Oncogene 25, 7019-7028 ; Chang et al. 2005, Prostaglandins & other Lipid Mediators 76, 48-58 ).
  • Endometriosis is a chronic condition caused by blood vessel disorders. About 10% of women regularly suffer from heavy bleeding during menstruation, caused by changes in the blood vessels of the endometrium. In addition, structural differences in the blood vessels were observed, such as incomplete smooth muscle cell layer formation ( Abberton et al., 1999, Hum. Reprod. 14, 1072-1079 ). Since blood loss during menstruation is in part governed by the constriction of the blood vessels, it is obvious that the smooth muscle defects contribute significantly to the bleeding.
  • the present invention is the use of the substances of general formula I for the treatment of endometriosis.
  • the present invention is the use of the substances of general formula I for the treatment of menstrual disorders.
  • Prostaglandins also play an important role in the processes that counteract bone loss.
  • the present invention therefore relates to the use of the substances according to the invention for the treatment of Bone loss.
  • Reinold et al. J. Clin. Invest. 115, 673-679 (2005 ) describes PGE 2 receptors of the EP 2 subtype as the key signaling elements in the inflammatory Hyperalgesia. Mice that no longer carry this receptor (EP 2 - / - ) do not experience spinal inflammatory pain. There are indications that an inflammatory, increased sensitivity to pain can be treated by specifically modulating EP 2 receptors.
  • the present invention is the use of the substances according to the invention for the treatment of inflammatory hyperalgesia.
  • Prostaglandins and especially the EP 2 receptor are also associated with ⁇ -amyloid genesis in Alzheimer's disease ( Hoshino et al. 2007 J Biol Chem .; 282 (45): 32676-3288 ).
  • the present invention is the use of the substances according to the invention for the prevention and treatment of Alzheimer's disease.
  • EP 2 receptor-mediated effects of PGE 2 are also associated with Parkinson's disease ( Jin et al. 2007; Journal of Neuroinflammation 1186 / 1742-2094-4-2 ).
  • the present invention is the use of the substances according to the invention for the prevention and treatment of Parkinson's disease.
  • the EP 2 receptor plays a role in inflammatory bowel disease (Crohn's disease, ulcerative colitis) because of its immunomodulatory effects ( Sheibanie et al. 2007; The Journal of Immunology, 178: 8138-8147 .)
  • the present invention is the use of the substances according to the invention for the prevention and treatment of inflammatory bowel diseases such as Crohn's disease, ulcerative colitis.
  • EP 2 receptor antagonists can enter Approach to the prevention and treatment of this disease ( Elberg et al. 2007, Am J Physiol Renal Physiol 293: F1622-F1632 .)
  • the present invention is the use of the substances according to the invention for the prevention and treatment of polycystic kidney diseases.
  • the EP 2 receptor is also associated with atherosclerotic engraftment processes ( Lie et al. 2006, Circ. Res.; 98: 642-650 ).
  • the present invention is the use of the substances according to the invention for the prevention and treatment of atherosclerosis.
  • Serezani et al. (At Respir Cell Mol Biol Vol. 37. pp 562-570, 2007 ) describes that via activation of the EP 2 receptor by PGE 2 , macrophages of the respiratory tract are impaired in their ability to destroy bacteria. Bacterial infections lead to increased production of prostaglandins, including PGE 2 , which weakens the body's defense against bacteria via this mechanism. As shown in this publication, by inactivating the EP 2 receptor (and the EP 4 receptor), this ability to fight bacteria can be restored. Other relevant publications that explain these relationships are: Sadikot et al. Eur. J. Immunol. 2007. 37: 1001-1009 and Aronoff et al. The Journal of Immunology, 2004, 173: 559-565 , The present invention is the use of the substances according to the invention for the treatment of infectious diseases of the lung.
  • the present invention therefore also relates to medicaments comprising a compound of the general formula (I) in combination with a COX inhibitor for the treatment of diseases.
  • COX inhibitors which may be mentioned are the non-selective COX inhibitors such as aspirin, naproxen, indomethacin, ibuprofen or the selective COX inhibitors meloxicam, celecoxib (4- [5- (4-methylphenyl) -3- (trifluoromethyl) -1H- pyrazol-1-yl] benzenesulfonamides) parecoxib (N- [4- (5-methyl-3-phenyl-4-isoxazolyl) phenyl] sulfonylpropionamide), rofecoxib (4- (4-mesylphenyl) -3-phenylfuran-2 (5H ) -one), valdecoxib (4- [5-methyl-3-phenyl-4-isoxazoyl) benzenesulf
  • carboxylic acid of general formula II by reagents such as HOBt (N-hydroxybenzotriazole) or HATU (o- (7-azabenzotriazol-1-yl) -N, N, N ', N'-te-tramethyluronium hexafluorophosphate).
  • HOBt N-hydroxybenzotriazole
  • HATU o- (7-azabenzotriazol-1-yl) -N, N, N ', N'-te-tramethyluronium hexafluorophosphate
  • Another possibility is to convert the acid function in the compounds of general formula II first by means of, for example, thionyl chloride, phosphorus oxychloride, phosphorus pentachloride or oxalyl chloride in the corresponding acid chloride and then the reaction to the compounds of general formula I, for example in pyridine or an inert solvent such as For example, DMF in the presence of the corresponding amine of the general formula III or IV and a tertiary Amine such as ethyldiisopropylamine at temperatures between - 50 ° C and + 60 ° C, preferably at 0 ° C to 30 ° C to perform.
  • the compounds of the general formula V by the methods known in the art in a CO 2 atmosphere, optionally under elevated pressure in the presence of a palladium catalyst, such as palladium diacetate, and a ligand, such as 1,3-bis (diphenylphosphino) -propane, and in the presence of an alcohol, preferably methanol or ethanol, and an inert solvent, such as dimethyl sulfoxide, converted into the corresponding methyl or ethyl esters and then by subsequent reaction, for example with aqueous sodium hydroxide solution in methanol and / or tetrahydrofuran, at 0 ° C to the boiling point of the solvent used, preferably between 30 ° C and 60 ° C, converted into the compounds of general formula II.
  • a palladium catalyst such as palladium diacetate
  • a ligand such as 1,3-bis (diphenylphosphino) -propane
  • an alcohol preferably methanol or ethanol
  • the compounds of the general formula V which are used as starting materials are either known or can be prepared, for example, by reacting carboxylic acids of the general formula VI in a manner known per se, wherein R 6 , R 9 , A 1 , A 2 , X and Y have the abovementioned meaning, with the amines of the general formula VII wherein R 1 to R 5 has the abovementioned meaning, according to the methods known in the art by activation of the acid function, analogously as in the methods for preparing the compounds of the general formula I as described above, are reacted.
  • the compounds of general formula XII are then refluxed by reaction of sodium or potassium cyanide in a solvent mixture, preferably DMF / water, into the C-extended nitrites which are subsequently reduced by lithium aluminum hydride in an inert solvent such as diethyl ether or tetrahydrofuran under reflux or alternatively by means of sodium borohydride / cobalt diacetate in ethanol or methanol, preferably at temperatures between 10 ° C and 40 ° C, the compounds of general formula VII.
  • a solvent mixture preferably DMF / water
  • protective groups are necessary for reactions, these can be prepared on precursors or for the required step according to the methods known to the person skilled in the art ( Protective groups in organic synthesis, TW Greene and PGM Wuts, John Wiley & Sons, 1999 ) and, if appropriate, subsequently split again or at a later stage of the synthesis.
  • Example 1 1H-Indole-2,5-dicarboxylic acid 5-carbamoylmethyl-amide 2 - ⁇ [2- (7-fluoro-2,4-dimethyl-1H-indol-3-yl) -ethyl] -amide ⁇
  • Example 2 1H-Indole-2,5-dicarboxylic acid 5 - [(2-dimethylamino-ethyl) -amide] 2 - ⁇ [2- (7-fluoro-2,4-dimethyl-1H-indol-3-yl) ethyl] amide ⁇
  • Example 3 1H-Indole-2,5-dicarboxylic acid 2 - ⁇ [2- (7-fluoro-2,4-dimethyl-1H-indol-3-yl) -ethyl] -amide ⁇ 5 - ⁇ [3- (3) 2-oxo-pyrrolidin-1-yl) -propyl] -amide ⁇
  • Example 4 1H-Indole-2,5-dicarboxylic acid 2 - ⁇ [2- (7-fluoro-2,4-dimethyl-1H-indol-3-yl) -ethyl] -amide ⁇ 5 - [(3-hydroxy -2,2-dimethyl-propyl) -amide]
  • Example 5 1H-Indole-2,5-dicarboxylic acid 5 - [(2-carbamoyl-ethyl) -amide] 2 - ⁇ [2- (7-fluoro-2,4-dimethyl-1H-indol-3-yl) ethyl] amide ⁇
  • Example 6 1H-Indole-2,6-dicarboxylic acid 6-carbamoylmethyl-amide 2 - ⁇ [2- (7-fluoro-2,4-dimethyl-1H-indol-3-yl) -ethyl] -amide ⁇
  • Example 7 1H-Indole-2,6-dicarboxylic acid 6 - [(2-dimethylamino-ethyl) -amide] 2 - ⁇ [2- (7-fluoro-2,4-dimethyl-1H-indol-3-yl) ethyl] amide ⁇
  • Example 8 1H-Indole-2,6-dicarboxylic acid 2 - ⁇ [2- (7-fluoro-2,4-dimethyl-1H-indol-3-yl) -ethyl] -amide ⁇ 6 - [(3-hydroxy -2,2-dimethyl-propyl) -amide]
  • Example 9 1H-Indole-2,6-dicarboxylic acid 2 - ⁇ [2- (7-fluoro-2,4-dimethyl-1H-indol-3-yl) -ethyl] -amide ⁇ 6 - ⁇ [3- (3) 2-oxo-pyrrolidin-1-yl) -propyl] -amide ⁇
  • Example 10 1H-Indole-2,6-dicarboxylic acid 6 - [(2-carbamoyl-ethyl) -amide] 2 - ⁇ [2- (7-fluoro-2,4-dimethyl-1H-indol-3-yl) ethyl] amide ⁇
  • the binding of PGE 2 to the EP 2 subtype of the human PGE 2 receptor induces the activation of membrane-bound adenylate cyclases and leads to the formation of cAMP.
  • the cAMP accumulated by this stimulation and liberated by cell lysis is used in a competitive detection procedure.
  • the cAMP in the lysate competes with cAMP-XL665 for the binding of an Eu-cryptate labeled anti-cAMP antibody.
  • Dissolved substance solutions (0.75 ⁇ l) in a test plate and 30% DMSO were dissolved in 16 ⁇ l of a KRSB + IBMX stimulation solution (1 X Krebs-Ringer bicarbonate buffer, Sigma-Aldrich # K-4002, including 750 ⁇ M 3-isobutyl-1 -methylxanthines Sigma-Aldrich # I-7018), then 15 ⁇ l thereof were transferred to a media-free cell culture plate which had been washed with KRSB shortly before.
  • IBMX stimulation solution (1 X Krebs-Ringer bicarbonate buffer, Sigma-Aldrich # K-4002, including 750 ⁇ M 3-isobutyl-1 -methylxanthines Sigma-Aldrich # I-7018
  • Dissolved substance solutions (0.75 ⁇ l) in a test plate and 30% DMSO were dissolved in 16 ⁇ l of a KRSB + IBMX stimulation solution (1 X Krebs-Ringer bicarbonate buffer, Sigma-Aldrich # K-4002, including 750 ⁇ M 3-isobutyl 1-methylxanthine Sigma-Aldrich # I-7018), then 15 ⁇ l thereof were transferred to a media-free cell culture plate which had been washed with KRSB shortly before. After a 60 minute incubation at room temperature (RT, volume: ⁇ 15 ⁇ l), the reaction was then stopped by addition of 5 ⁇ l lysis buffer and incubated for a further 20 min at RT (volume: ⁇ 20 ⁇ l). The cell lysate was then transferred to a measuring plate and measured according to the manufacturer's instructions (cyclic AMP kit Cisbio International # 62AMPPEC).
  • the oocyte In the pre-ovulatory antral follicle, the oocyte is surrounded by cumulus cells, which form a dense cell ring around the egg. After the LH peak (Luteinizing Hormone), a number of processes are activated, resulting in a strong morphological change of this cell cluster of cumulus cells. Here, the cumulus cells form an extracellular matrix, the so-called cumulus expansion leads ( Vanderhyden et al. Dev Biol. 1990 Aug; 140 (2): 307-317 ). This cumulus expansion is an important part of the ovulatory process and the subsequent possibility of fertilization.
  • LH peak Liuteinizing Hormone
  • Prostanoid EP 2 knock-out mice show markedly reduced cumulus expansion and strong subfertility, demonstrating the importance of the prostanoid EP 2 receptor for this process.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP08161444A 2008-07-30 2008-07-30 Indolylamides en tant que modulateurs du récepteur EP2 Withdrawn EP2149554A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP08161444A EP2149554A1 (fr) 2008-07-30 2008-07-30 Indolylamides en tant que modulateurs du récepteur EP2
PCT/EP2009/005267 WO2010012399A1 (fr) 2008-07-30 2009-07-21 Indolyl-amides comme modulateurs du récepteur ep<sb>2</sb>

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08161444A EP2149554A1 (fr) 2008-07-30 2008-07-30 Indolylamides en tant que modulateurs du récepteur EP2

Publications (1)

Publication Number Publication Date
EP2149554A1 true EP2149554A1 (fr) 2010-02-03

Family

ID=39938245

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08161444A Withdrawn EP2149554A1 (fr) 2008-07-30 2008-07-30 Indolylamides en tant que modulateurs du récepteur EP2

Country Status (2)

Country Link
EP (1) EP2149554A1 (fr)
WO (1) WO2010012399A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017126635A1 (fr) * 2016-01-22 2017-07-27 武田薬品工業株式会社 Composé hétérocyclique et utilisation de celui-ci
WO2023125376A1 (fr) * 2021-12-27 2023-07-06 上海京新生物医药有限公司 Composé hétéroarylamide bicyclique fusionné utile en tant qu'inhibiteur de l'agrégation de protéines
WO2025002040A1 (fr) * 2023-06-25 2025-01-02 上海京新生物医药有限公司 Forme cristalline ou sel d'un composé hétéroaryle bicyclique amide, son procédé de préparation et son utilisation

Citations (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0860430A2 (fr) 1997-02-04 1998-08-26 Ono Pharmaceutical Co., Ltd. Dérivés omega-cycloalkyl-prostaglandine E2
WO1999019300A1 (fr) 1997-10-10 1999-04-22 Pfizer Inc. Agonistes de la prostaglandine et leur utilisation pour le traitement des problemes osseux
WO2000018744A1 (fr) * 1998-09-25 2000-04-06 Fujisawa Pharmaceutical Co., Ltd. Composes d'oxazole convenant comme agonistes ou antagonistes de la prostaglandine e2
US6410591B1 (en) 2001-05-08 2002-06-25 Allergan Sales, Inc. 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
WO2003009872A1 (fr) 2001-07-23 2003-02-06 Ono Pharmaceutical Co., Ltd. Medicaments contenant un agoniste de ep4 en tant que principe actif destines aux maladies associees a une perte de la masse osseuse
WO2003016254A1 (fr) 2001-08-09 2003-02-27 Ono Pharmaceutical Co., Ltd. Composes derives d'acide carboxylique et medicaments comprenant ces composes comme principe actif
WO2003035064A1 (fr) 2001-10-23 2003-05-01 Applied Research Systems Ars Holding N.V. Composes de pyrazolidinone utilises comme ligands des recepteurs ep2 et/ou ep4 aux prostaglandines
EP1306087A1 (fr) 2000-07-31 2003-05-02 Ono Pharmaceutical Co., Ltd. Remedes contre la dyserection contenant des derives de prostaglandine comme principe actif
WO2003037433A1 (fr) 2001-10-26 2003-05-08 Allergan, Inc. Analogues e2 de prostaglandine co-cycloalkyle 17-heteroaryle utilises en tant qu'agonistes du recepteur ep¿2?
WO2003040123A1 (fr) 2001-11-07 2003-05-15 Biosilvio Munkfors Ab Emploi de zeolites comme matrices
WO2003045371A1 (fr) 2001-11-30 2003-06-05 Pfizer Products Inc. Compositions pharmaceutiques et methodes d'administration d'agonistes selectifs de recepteur ep2
WO2003047513A2 (fr) 2001-12-03 2003-06-12 Merck & Co., Inc. Methode de traitement de l'hypertension oculaire
WO2003047417A2 (fr) 2001-12-03 2003-06-12 Merck & Co., Inc. Agoniste du recepteur ep4, compositions et procedes associes
WO2003053923A2 (fr) 2001-12-20 2003-07-03 Applied Research Systems Ars Holding N.V. Derives de pyrrolidine utilises en tant que modulateurs de la prostaglandine
WO2003064391A1 (fr) 2002-01-31 2003-08-07 Pfizer Products Inc. Metabolites d'acide (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetique
WO2003074483A1 (fr) 2002-03-05 2003-09-12 Ono Pharmaceutical Co., Ltd. Composes derives de 8 azaprostaglandine et medicaments contenant ceux-ci comme principe actif
WO2003077910A1 (fr) 2002-03-18 2003-09-25 Pfizer Products Inc. Procedes de traitement au moyen d'agonistes selectifs du recepteur ep4
WO2003077919A1 (fr) 2002-03-13 2003-09-25 Merck & Co., Inc. Derives de 4-azasteroide fluore en tant que modulateur de recepteur androgenique
WO2003103604A2 (fr) 2002-06-01 2003-12-18 Applied Research Systems Ars Holding N.V Gamma lactames utilises en tant qu'agonistes de la prostaglandine et leur utilisation
WO2003103772A1 (fr) 2002-06-06 2003-12-18 Merck Frosst Canada & Co. Derives de pyrrolid-2-one 1,5 disubstitues utilises comme agonistes de recepteur ep4 pour traiter des maladies oculaires telles que le glaucome
WO2003103664A1 (fr) 2002-06-06 2003-12-18 Merck Frosst Canada & Co. Derives d'imidazolidine-2-one disubstitues en 1,5 utiles en tant qu'agonistes du recepteur ep4 dans le traitement de troubles oculaires et de maladies osseuses
WO2004009117A1 (fr) 2002-07-18 2004-01-29 Ono Pharmaceutical Co., Ltd. Agent tocolytique comprenant comme principe actif un agoniste de ep2
WO2004012656A2 (fr) 2002-08-02 2004-02-12 Applied Research Systems Ars Holding N.V. Derives de thiophene et de furanne en tant qu'agonistes de la prostaglandine et utilisation associee
WO2004019938A1 (fr) 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Derives de l'oxazolidin-2-one et de la thiazolidin-2-one antagonistes du recepteur ep4, pour le traitement du glaucome
WO2004032964A1 (fr) 2002-10-10 2004-04-22 Ono Pharmaceutical Co., Ltd. Remedes pour affections allergiques
WO2004037813A1 (fr) 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Derives de pyrrolidine-2-one en tant qu'agonistes du recepteur ep4
WO2004037786A2 (fr) 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Agonistes des recepteurs ep4
WO2004039807A1 (fr) 2002-10-30 2004-05-13 Merck Frosst Canada & Co. Pyridopyrrolizine et derives de pyridoindolizine
US20040102508A1 (en) 2000-12-21 2004-05-27 Giblin Gerard Martin Paul Naphathalene derivatives which bind to the ep4 receptor
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
EP1467738A1 (fr) 2001-10-08 2004-10-20 Medical Research Council Utilisation d'inhibiteurs de la prostaglandine e synthase ou d'antagonistes du recepteur ep2 ou ep4 dans le traitement d'une affection de l'uterus
US20050059742A1 (en) 2001-10-31 2005-03-17 Jabbour Henry Nicolas Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorphagia
WO2005035514A2 (fr) 2003-10-08 2005-04-21 Vertex Pharmaceuticals Incorporated Modulateurs des transporteurs des cassettes de fixation de l'atp
WO2005080367A1 (fr) * 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Agonistes des recepteurs ep2
JP2007045752A (ja) 2005-08-10 2007-02-22 Takeda Chem Ind Ltd ５員芳香族複素環誘導体、その製造法および用途
WO2007057232A1 (fr) 2005-11-21 2007-05-24 Bayer Schering Pharma Aktiengesellschaft Derives de la 9-chloro-15-desoxyprostaglandine, leurs procedes de preparation et leur utilisation en tant que medicaments
WO2007071456A1 (fr) 2005-12-22 2007-06-28 Bayer Schering Pharma Aktiengesellschaft Fluorenes et carbazoles utilises en tant que ligands du recepteur ep2
WO2008028690A1 (fr) 2006-09-07 2008-03-13 Bayer Schering Pharma Aktiengesellschaft 1-(hét)aryle-3-[hétaryle-pipéridine-4-yle]-thiourées utilisées en tant que modulateurs du récepteur ep2
WO2008028691A1 (fr) 2006-09-07 2008-03-13 Bayer Schering Pharma Aktiengesellschaft N-(1-hétarylpipéridine-4-yl)(hét)arylamides utilisés en tant que modulateurs du récepteur ep2
WO2008028689A1 (fr) 2006-09-07 2008-03-13 Bayer Schering Pharma Aktiengesellschaft N-(1-phtalazine-1-ylpipéridine-4-yl)amides utilisés comme modulateurs du récepteur de ep2

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2002834A1 (fr) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryle/hétarylamides en tant que modulateurs du récepteur EP2

Patent Citations (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0860430A2 (fr) 1997-02-04 1998-08-26 Ono Pharmaceutical Co., Ltd. Dérivés omega-cycloalkyl-prostaglandine E2
WO1999019300A1 (fr) 1997-10-10 1999-04-22 Pfizer Inc. Agonistes de la prostaglandine et leur utilisation pour le traitement des problemes osseux
WO2000018744A1 (fr) * 1998-09-25 2000-04-06 Fujisawa Pharmaceutical Co., Ltd. Composes d'oxazole convenant comme agonistes ou antagonistes de la prostaglandine e2
EP1306087A1 (fr) 2000-07-31 2003-05-02 Ono Pharmaceutical Co., Ltd. Remedes contre la dyserection contenant des derives de prostaglandine comme principe actif
US20040102508A1 (en) 2000-12-21 2004-05-27 Giblin Gerard Martin Paul Naphathalene derivatives which bind to the ep4 receptor
US6410591B1 (en) 2001-05-08 2002-06-25 Allergan Sales, Inc. 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
WO2003009872A1 (fr) 2001-07-23 2003-02-06 Ono Pharmaceutical Co., Ltd. Medicaments contenant un agoniste de ep4 en tant que principe actif destines aux maladies associees a une perte de la masse osseuse
EP1431267A1 (fr) * 2001-08-09 2004-06-23 Ono Pharmaceutical Co., Ltd. Composes derives d'acide carboxylique et medicaments comprenant ces composes comme principe actif
WO2003016254A1 (fr) 2001-08-09 2003-02-27 Ono Pharmaceutical Co., Ltd. Composes derives d'acide carboxylique et medicaments comprenant ces composes comme principe actif
EP1467738A1 (fr) 2001-10-08 2004-10-20 Medical Research Council Utilisation d'inhibiteurs de la prostaglandine e synthase ou d'antagonistes du recepteur ep2 ou ep4 dans le traitement d'une affection de l'uterus
WO2003035064A1 (fr) 2001-10-23 2003-05-01 Applied Research Systems Ars Holding N.V. Composes de pyrazolidinone utilises comme ligands des recepteurs ep2 et/ou ep4 aux prostaglandines
WO2003037433A1 (fr) 2001-10-26 2003-05-08 Allergan, Inc. Analogues e2 de prostaglandine co-cycloalkyle 17-heteroaryle utilises en tant qu'agonistes du recepteur ep¿2?
US20050059742A1 (en) 2001-10-31 2005-03-17 Jabbour Henry Nicolas Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorphagia
WO2003040123A1 (fr) 2001-11-07 2003-05-15 Biosilvio Munkfors Ab Emploi de zeolites comme matrices
WO2003045371A1 (fr) 2001-11-30 2003-06-05 Pfizer Products Inc. Compositions pharmaceutiques et methodes d'administration d'agonistes selectifs de recepteur ep2
US20030166631A1 (en) 2001-11-30 2003-09-04 Francis Dumont Pharmaceutical compositions and methods for administering EP2 receptor selective agonists
WO2003047417A2 (fr) 2001-12-03 2003-06-12 Merck & Co., Inc. Agoniste du recepteur ep4, compositions et procedes associes
WO2003047513A2 (fr) 2001-12-03 2003-06-12 Merck & Co., Inc. Methode de traitement de l'hypertension oculaire
WO2003053923A2 (fr) 2001-12-20 2003-07-03 Applied Research Systems Ars Holding N.V. Derives de pyrrolidine utilises en tant que modulateurs de la prostaglandine
US20050124577A1 (en) 2002-01-22 2005-06-09 Kousuke Tani 8-Azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
WO2003064391A1 (fr) 2002-01-31 2003-08-07 Pfizer Products Inc. Metabolites d'acide (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetique
WO2003074483A1 (fr) 2002-03-05 2003-09-12 Ono Pharmaceutical Co., Ltd. Composes derives de 8 azaprostaglandine et medicaments contenant ceux-ci comme principe actif
WO2003077919A1 (fr) 2002-03-13 2003-09-25 Merck & Co., Inc. Derives de 4-azasteroide fluore en tant que modulateur de recepteur androgenique
WO2003077910A1 (fr) 2002-03-18 2003-09-25 Pfizer Products Inc. Procedes de traitement au moyen d'agonistes selectifs du recepteur ep4
WO2003103604A2 (fr) 2002-06-01 2003-12-18 Applied Research Systems Ars Holding N.V Gamma lactames utilises en tant qu'agonistes de la prostaglandine et leur utilisation
WO2003103772A1 (fr) 2002-06-06 2003-12-18 Merck Frosst Canada & Co. Derives de pyrrolid-2-one 1,5 disubstitues utilises comme agonistes de recepteur ep4 pour traiter des maladies oculaires telles que le glaucome
WO2003103664A1 (fr) 2002-06-06 2003-12-18 Merck Frosst Canada & Co. Derives d'imidazolidine-2-one disubstitues en 1,5 utiles en tant qu'agonistes du recepteur ep4 dans le traitement de troubles oculaires et de maladies osseuses
WO2004009117A1 (fr) 2002-07-18 2004-01-29 Ono Pharmaceutical Co., Ltd. Agent tocolytique comprenant comme principe actif un agoniste de ep2
WO2004012656A2 (fr) 2002-08-02 2004-02-12 Applied Research Systems Ars Holding N.V. Derives de thiophene et de furanne en tant qu'agonistes de la prostaglandine et utilisation associee
WO2004019938A1 (fr) 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Derives de l'oxazolidin-2-one et de la thiazolidin-2-one antagonistes du recepteur ep4, pour le traitement du glaucome
WO2004032964A1 (fr) 2002-10-10 2004-04-22 Ono Pharmaceutical Co., Ltd. Remedes pour affections allergiques
WO2004037786A2 (fr) 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Agonistes des recepteurs ep4
WO2004037813A1 (fr) 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Derives de pyrrolidine-2-one en tant qu'agonistes du recepteur ep4
WO2004039807A1 (fr) 2002-10-30 2004-05-13 Merck Frosst Canada & Co. Pyridopyrrolizine et derives de pyridoindolizine
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
WO2005035514A2 (fr) 2003-10-08 2005-04-21 Vertex Pharmaceuticals Incorporated Modulateurs des transporteurs des cassettes de fixation de l'atp
WO2005080367A1 (fr) * 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Agonistes des recepteurs ep2
JP2007045752A (ja) 2005-08-10 2007-02-22 Takeda Chem Ind Ltd ５員芳香族複素環誘導体、その製造法および用途
WO2007057232A1 (fr) 2005-11-21 2007-05-24 Bayer Schering Pharma Aktiengesellschaft Derives de la 9-chloro-15-desoxyprostaglandine, leurs procedes de preparation et leur utilisation en tant que medicaments
WO2007071456A1 (fr) 2005-12-22 2007-06-28 Bayer Schering Pharma Aktiengesellschaft Fluorenes et carbazoles utilises en tant que ligands du recepteur ep2
WO2008028690A1 (fr) 2006-09-07 2008-03-13 Bayer Schering Pharma Aktiengesellschaft 1-(hét)aryle-3-[hétaryle-pipéridine-4-yle]-thiourées utilisées en tant que modulateurs du récepteur ep2
WO2008028691A1 (fr) 2006-09-07 2008-03-13 Bayer Schering Pharma Aktiengesellschaft N-(1-hétarylpipéridine-4-yl)(hét)arylamides utilisés en tant que modulateurs du récepteur ep2
WO2008028689A1 (fr) 2006-09-07 2008-03-13 Bayer Schering Pharma Aktiengesellschaft N-(1-phtalazine-1-ylpipéridine-4-yl)amides utilisés comme modulateurs du récepteur de ep2

Non-Patent Citations (35)

* Cited by examiner, † Cited by third party
Title
ABBERTON ET AL., HUM. REPROD, vol. 14, 1999, pages 1072 - 1079
ARONOFF ET AL., JOURNAL OF IMMUNOLOGY, vol. 173, 2004, pages 559 - 565
CASTELLONE ET AL., SCIENCE, vol. 310, 2005, pages 1504 - 1510
CHANG ET AL., CANCER RES, vol. 65, no. 11, 2005, pages 4496 - 9
CHANG ET AL., PROSTAGLANDINS & OTHER LIPID MEDIATORS, vol. 76, 2005, pages 48 - 58
CHEM. REV., 2006, pages 2875
ELBERG ET AL., AM J PHYSIOL RENAL PHYSIOL, vol. 293, 2007, pages F1622 - F1632
FULTON ET AL., CANCER RES, vol. 66, no. 20, 2006, pages 9794 - 7
HERMAN Z S ET AL: "Basic pharmacological properties of a novel anti-inflammatory drug tryptamide", POLISH JOURNAL OF PHARMACOLOGY AND PHARMACY, PHARMACOLOGY, KRAKOW, vol. 39, no. 6, 1 January 1987 (1987-01-01), pages 729 - 736, XP008085789, ISSN: 0301-0244 *
HIZAKI ET AL., PROC NATL ACAD SCI U. S. A., vol. 96, no. 18, 31 August 1999 (1999-08-31), pages 10501 - 10506
HIZAKI ET AL., PROC NATL ACAD SCI USA., vol. 96, no. 18, 31 August 1999 (1999-08-31), pages 10501 - 6
HOSHINO ET AL., J BIOL CHEM., vol. 282, no. 45, 2007, pages 32676 - 3288
HULL ET AL., MOL CANCER THER, vol. 3, no. 8, 2004, pages 1031 - 9
J. CHEM. SOC., PERKIN TRANS 1, 2000, pages 1045
JABBOUR, MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 252, 2006, pages 191 - 200
JIN ET AL., JOURNAL OF NEUROINFLAMMATION, 2007
KAMIYAMA ET AL., ONCOGENE, vol. 25, 2006, pages 7019 - 7028
KUWANO ET AL., FASEB J., vol. 18, 2004, pages 300 - 310
LIE ET AL., CIRC RES., vol. 98, 2006, pages 642 - 650
MATSUMOTO ET AL., BIOLOGY OF REPRODUCTION, vol. 64, 2001, pages 1557 - 1565
ORG. LETT., 2004, pages 79FF
PAN ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 283, no. 17, 2008, pages 11155 - 11163
REINOLD ET AL., J. CLIN. INVEST., vol. 115, 2005, pages 673 - 679
RICHARDS ET AL., J CLIN ENDOCRINOL METAB, vol. 88, 2003, pages 2810 - 2816
SADIKOT ET AL., EUR. J. IMMUNOL, vol. 37, 2007, pages 1001 - 1009
SALES; JABBOUR, REPRODUCTION, vol. 126, 2003, pages 559 - 567
SEREZANI ET AL., AM RESPIR CELL MOL BIOL, vol. 37, 2007, pages 562 - 570
SHEIBANIE ET AL., JOURNAL OF IMMUNOLOGY, vol. 178, 2007, pages 8138 - 8147
SINHA ET AL., CANCER RES, vol. 67, no. 9, 2007, pages 4507 - 13
SMITH ET AL., HUMAN REPRODUCTION, vol. 22, no. 5, 2007, pages 1450 - 1456
SUBBARAMAIAH ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 283, no. 6, 2008, pages 3433 - 3444
T. W. GREENE; P. G. M. WUTS: "Protective groups in organic synthesis", 1999, JOHN WILEY & SONS
VANDERHYDEN ET AL., DEV BIOL, vol. 140, no. 2, August 1990 (1990-08-01), pages 307 - 317
VANDERHYDEN ET AL., DEV BIOL., vol. 140, no. 2, August 1990 (1990-08-01), pages 307 - 317
WANG ET AL., SEMINARS IN ONCOLOGY, vol. 31, no. 1, 2004, pages 64 - 73

Also Published As

Publication number Publication date
WO2010012399A1 (fr) 2010-02-04

Similar Documents

Publication Publication Date Title
EP2149551A1 (fr) Dérivés de N-(indol-3-ylalkyl)-(hétéro)arylamide en tant que modulateurs du récepteur EP2
EP2002834A1 (fr) Aryle/hétarylamides en tant que modulateurs du récepteur EP2
EP2003118A1 (fr) Dérivés d&#39;acides de cannelle en tant que modulateurs du récepteur EP2
EP2928884B1 (fr) Nouveaux dérivés du benzimidazole comme antagonistes ep4
EP3083603B1 (fr) Dérivés de benzimidazole en tant que ligands de ep4
DE60112272T2 (de) Imidazopyridin-derivate
DE60118564T2 (de) Propan-1,3-dion-derivate
EP2149552A1 (fr) Dérivés de benzamide 5,6 substitués en tant que modulateurs du récepteur EP2
DE69906940T2 (de) Bizyclische pyrrolverbindungen, deren pharmazeutische zusammensetzungen und ihre verwendung als entzündungshemmende und immunmodulierende mittel
DE60005355T2 (de) Bradikinin b1 rezeptor antagonisten
EP2014657A1 (fr) Diaminopyrimidine en tant que modulateurs du récepteur EP2
EP2002838A1 (fr) Utilisation de dérivés d&#39;aryle/hétarylamide en tant que modulateurs du récepteur EP2
DE69118388T2 (de) Substituierte bizyklische arylderivate mit selektiver leukotrien b4 antagonistischer wirkung
EP1903038A1 (fr) Dérivés N-(1-hetaryl-piperidine-4-yl)-(het)arylamide utilisées comme modulateurs du recepteur EP2
JPH07215947A (ja) １−ベンゼンスルホニル−１，３−ジヒドロ−２ｈ−ベンズイミダゾール−２−オン誘導体
DE4333254A1 (de) Piperidine und Piperazine
CN104606194A (zh) Pde4的双环杂芳基抑制剂
JP2006509014A (ja) メラノコルチンレセプターの調節因子
WO2000068206A1 (fr) Benzimidazoles substitues par voie heterocyclique, leur production et leur application
JP2021152056A (ja) 疾患を治療するためのｍｃｔ４阻害剤
EP1900731A1 (fr) N-(1-Phthalazin-1-yl-piperidin-4-yl)-amides comme modulateurs du récepteur EP2
EP2014663A1 (fr) Thienopyrimidylamine en tant que modulateurs du récepteur EP2
JP2020500916A (ja) Ｍｃｔ４の複素環阻害剤
WO2008028690A1 (fr) 1-(hét)aryle-3-[hétaryle-pipéridine-4-yle]-thiourées utilisées en tant que modulateurs du récepteur ep2
EP2003119A1 (fr) Acétamides substitués en tant que modulateurs du récepteur EP2

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

AKY No designation fees paid
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100804

REG Reference to a national code

Ref country code: DE

Ref legal event code: R108

Effective date: 20110309

Ref country code: DE

Ref legal event code: 8566